Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study

Abstract

PAD as initial manifestation of atherosclerotic disease diagnosed in a hospital-based setting conferred a high risk: one in eight patients experienced a major CV event and one in six patients died within 1 year. Despite younger age and substantial risk of future major CV events, patients with primary PAD received less intensive secondary preventive drug therapy.

Peripheral Arterial Disease and Its Associated Factors among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia

“…It is a major complication of atherosclerosis [8] as well as a manifestation of atherosclerosis in major blood vessels like coronary and cerebral arteries [9,10]. It results in systemic atherothrombosis that leads to cerebrovascular events, including myocardial infarction, stroke, significant long-term disability, and death [9,[11][12][13]. Diabetic patients with PAD are at high risk of increased morbidity and mortality from cardiovascular diseases and a high rate of lower extremity amputation [7,[14][15][16].…”

Alt Ekstremite İskemisi Nedeniyle Endovasküler Girişim Planlanan Hastaların Klinik Sonuçları ve Koroner Arter Hastalığı Açısından Değerlendirilmesi

“…The incidence of these events were 12% in patients having only PAD while one-year CV events were found to be as high as 21% in patients with PAD along with CAD. 17 Consistently, Sigvant et al…”

Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials

“…Patients with early‐onset atherosclerosis, atherosclerotic disease in another vascular bed, DM, or end‐stage renal disease have a higher risk for progression of PAD and overall worse prognosis . PAD is associated with poor cardiovascular (CV) outcomes, including myocardial infarction (MI), ischemic stroke, and death . Symptomatic PAD patients carry a higher mortality rate than those with asymptomatic disease, although both carry significant risks for poor CV outcomes …”